Benchmark reduced its price target and set a buy rating for Abbott Laboratories, while Royal Bank of Canada issued an outperform rating on July 29, 2026.
2 reports, 1 independent
Updated Sep 8
Gone quiet
- Reports
- 2
- Developments
- 1
- Repetition
- 50%
New informationRepeats or wire copies
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
Benchmark reduced its price target and set a buy rating for Abbott Laboratories, while Royal Bank of Canada issued an outperform rating on July 29, 2026.
Who's involved
What this event is mainly aboutKeep exploring
The entities involved
-
Abbott Laboratories
American global health care and medical device products company
-
Benchmark
venture capital firm
- The Bank of England, FED, and market experts are discussing how the ongoing Iran conflict and geopolitical tensions are driving up energy costs and influencing global financial rates.
- MarketBeat published a buy rating and target price increase for a company, with disclosures made under a Rule 10b5-1 trading plan.
-
Royal Bank of Canada
financial institution in Canada
Related events
- Royal Bank of Canada provided a price target and reaffirmed a sector perform rating for Plains All American Pipeline.
- RBC and Truist Financial issued rating updates and price targets for LINE.
- Analyst raised price target and gave outperform rating for Aramark on August 19, 2026.
- Royal Bank of Canada and Leerink Partners lowered price targets and ratings for Boston Scientific.
- Royal Bank of Canada lowered its target price for Arthur J. Gallagher & Co. in a research report.